Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Radiochemotherapy in Glioblastoma
NCT06418113Phase 1Recruiting
- Sponsor
- Hospital Clínico San Carlos
- Start
- Mar 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of temozolomide in glioblastoma (GBM) (2 arms), sponsored by Hospital Clínico San Carlos. Primary endpoints: Emergent Adverse Events assessed by physical and neurological examination at 2 years, Emergent Adverse Events assessed by hematology and biochemistry at 2 years and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06418113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06418113.